Literature DB >> 24097859

It takes two to tango: Dual inhibition of PI3K and MAPK in rhabdomyosarcoma.

Arman Jahangiri1, William A Weiss.   

Abstract

The PI3K/AKT/mTOR and RAS/RAF/MAPK pathways play essential roles in rhabdomyosarcoma. Singular targeting of each pathway is ineffective due to extensive cross-talk and compensatory feedback between these two pathways. Dual blockade with inhibitors of PI3K and MAPK in combination synergistically inhibits growth of rhabdomyosarcoma both in vitro and in vivo.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24097859      PMCID： PMC3828201          DOI： 10.1158/1078-0432.CCR-13-2177

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  Recognizing and exploiting differences between RNAi and small-molecule inhibitors.

Authors:  William A Weiss; Stephen S Taylor; Kevan M Shokat
Journal:  Nat Chem Biol       Date:  2007-12       Impact factor: 15.040

Review 2.  The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.

Authors:  Antonella De Luca; Monica R Maiello; Amelia D'Alessio; Maria Pergameno; Nicola Normanno
Journal:  Expert Opin Ther Targets       Date:  2012-03-23       Impact factor: 6.902

3.  The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

Authors:  Toshio Shimizu; Anthony W Tolcher; Kyriakos P Papadopoulos; Muralidhar Beeram; Drew W Rasco; Lon S Smith; Shelly Gunn; Leslie Smetzer; Theresa A Mays; Brianne Kaiser; Michael J Wick; Cathy Alvarez; Aracely Cavazos; Gina L Mangold; Amita Patnaik
Journal:  Clin Cancer Res       Date:  2012-01-19       Impact factor: 12.531

4.  Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma.

Authors:  Birgit Geoerger; Mark W Kieran; Stephan Grupp; Danuta Perek; Jill Clancy; Mizue Krygowski; Revathi Ananthakrishnan; Joseph P Boni; Anna Berkenblit; Sheri L Spunt
Journal:  Eur J Cancer       Date:  2011-10-25       Impact factor: 9.162

5.  Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival.

Authors:  Emanuel F Petricoin; Virginia Espina; Robyn P Araujo; Brieanne Midura; Choh Yeung; Xiaolin Wan; Gabriel S Eichler; Donald J Johann; Stephen Qualman; Maria Tsokos; Kartik Krishnan; Lee J Helman; Lance A Liotta
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

6.  Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.

Authors:  Y N Vashisht Gopal; Wanleng Deng; Scott E Woodman; Kakajan Komurov; Prahlad Ram; Paul D Smith; Michael A Davies
Journal:  Cancer Res       Date:  2010-10-19       Impact factor: 12.701

7.  Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.

Authors:  Kathryn Balmanno; Simon D Chell; Annette S Gillings; Shaista Hayat; Simon J Cook
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

8.  Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  D Joshi; James R Anderson; C Paidas; J Breneman; D M Parham; W Crist
Journal:  Pediatr Blood Cancer       Date:  2004-01       Impact factor: 3.167

9.  RAS signaling dysregulation in human embryonal Rhabdomyosarcoma.

Authors:  Simone Martinelli; Heather P McDowell; Silvia Delle Vigne; George Kokai; Stefania Uccini; Marco Tartaglia; Carlo Dominici
Journal:  Genes Chromosomes Cancer       Date:  2009-11       Impact factor: 5.006

10.  Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Authors:  Jeffrey A Engelman; Liang Chen; Xiaohong Tan; Katherine Crosby; Alexander R Guimaraes; Rabi Upadhyay; Michel Maira; Kate McNamara; Samanthi A Perera; Youngchul Song; Lucian R Chirieac; Ramneet Kaur; Angela Lightbown; Jessica Simendinger; Timothy Li; Robert F Padera; Carlos García-Echeverría; Ralph Weissleder; Umar Mahmood; Lewis C Cantley; Kwok-Kin Wong
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440
View more
  6 in total

1.  Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.

Authors:  Vivek Subbiah; Christian Meyer; Ralph Zinner; Funda Meric-Bernstam; Marianna L Zahurak; Ashley O'Connor; Jason Roszik; Kenna Shaw; Joseph A Ludwig; Razelle Kurzrock; Nilofer A Azad
Journal:  Clin Cancer Res       Date:  2017-04-04       Impact factor: 12.531

2.  Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer.

Authors:  Shannon N Westin; Marilyne Labrie; Jennifer K Litton; Aurora Blucher; Yong Fang; Christopher P Vellano; Joseph R Marszalek; Ningping Feng; XiaoYan Ma; Allison Creason; Bryan Fellman; Ying Yuan; Sanghoon Lee; Tae-Beom Kim; Jinsong Liu; Anca Chelariu-Raicu; Tsun Hsuan Chen; Nashwa Kabil; Pamela T Soliman; Michael Frumovitz; Katheleen M Schmeler; Amir Jazaeri; Karen H Lu; Rashmi Murthy; Larissa A Meyer; Charlotte C Sun; Anil K Sood; Robert L Coleman; Gordon B Mills
Journal:  Clin Cancer Res       Date:  2021-09-13       Impact factor: 13.801

3.  Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches.

Authors:  Tetyana Tegnebratt; Elisabeth Ruge; Sabine Bader; Nobuya Ishii; Satoshi Aida; Yasushi Yoshimura; Chia-Huey Ooi; Li Lu; Nicholas Mitsios; Valerie Meresse; Jan Mulder; Michael Pawlak; Miro Venturi; Jean Tessier; Sharon Stone-Elander
Journal:  EJNMMI Res       Date:  2014-09-09       Impact factor: 3.138

4.  Combined application of arsenic trioxide and lithium chloride augments viability reduction and apoptosis induction in human rhabdomyosarcoma cell lines.

Authors:  Sabine B Schleicher; Julian J Zaborski; Rosa Riester; Natascha Zenkner; Rupert Handgretinger; Torsten Kluba; Frank Traub; Karen A Boehme
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

5.  The c-Myc/AKT1/TBX3 Axis Is Important to Target in the Treatment of Embryonal Rhabdomyosarcoma.

Authors:  Danica Sims; Hapiloe Mabaruti Maranyane; Victoria Damerell; Dhirendra Govender; Ashwin W Isaacs; Jade Peres; Sharon Prince
Journal:  Cancers (Basel)       Date:  2020-02-21       Impact factor: 6.639

6.  Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer.

Authors:  Alexandra Canonici; Alacoque L Browne; Mohamed F K Ibrahim; Kevin P Fanning; Sandra Roche; Neil T Conlon; Fiona O'Neill; Justine Meiller; Mattia Cremona; Clare Morgan; Bryan T Hennessy; Alex J Eustace; Flavio Solca; Norma O'Donovan; John Crown
Journal:  Ther Adv Med Oncol       Date:  2020-01-28       Impact factor: 8.168
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.